



EUROPEAN COMMISSION  
JOINT RESEARCH CENTRE  
Directorate F – Health and Food  
**Disease Prevention**

## **Annual Declaration of Interests<sup>1</sup> (DoI) form (v1, 30 June 2025)**

European Commission initiative on Breast Cancer (ECIBC)

**Please answer each of the questions below.**

**If the answer to any of the questions is "Yes"<sup>2</sup>, please complete the corresponding fields, describing the circumstances, as appropriate.**

**If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the ECIBC activities.**

**If you do not disclose relevant activities of interest for the ECIBC, your role may be revised.**

---

<sup>1</sup> According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form

[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

<sup>2</sup> Answering "Yes" to the questions on this form does not automatically limit your participation in the ECIBC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

<b>Name and Surname:</b>	<b>Prof. Dr. Annette Lebeau</b>
--------------------------	---------------------------------

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>1. Do you have current investments<sup>3</sup> in a legal entity<sup>4</sup> with an interest related to breast cancer which either:</b> <ul style="list-style-type: none"> <li>• has a value of more than 10.000 EUR, or</li> <li>• entitles you to a voting right of 5% or more?</li> </ul>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of entity;</li> <li>• Place;</li> <li>• Type of entity: public, private.</li> </ul>	[Please describe your role.]

<sup>3</sup> **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

<sup>4</sup> **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<p><b>2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to breast cancer?</b></p> <p><b>A. Employment</b></p>	<p>Yes <input type="checkbox"/></p> <p>No <input checked="" type="checkbox"/></p>	<p>MM/YYYY</p> <p>–</p> <p>MM/YYYY</p>	<p>If 'yes', please specify:</p> <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of entity: public, private;</li> <li>• Received amounts for remunerated activities.</li> </ul>	<p>[Please describe your role.]</p>

<b>B. Consultancy, including advisory activities</b>	Yes <input checked="" type="checkbox"/>	9/2021-present	- Roche Pharma AG, Grenzach-Whylen honorary and travel fees : € 5.193.58	Consultant and lecture activities (biomarker testing; e. g. PIK3CA testing)
	No <input type="checkbox"/>	11/2021	- MSD Sharp & Dohme GmbH, Germany honorary : € 1.200	Lecture activities (e. g. PD-L1 testing)
		9/2021 - present	- Daiichi Sankyo Europe GmbH honorary and travel fees: € 10.971	Consultant, lecture activities and member of steering committee (HER2 low/ultralow testing)
		9/2021 - present	- AstraZeneca, Germany travel fees and honorary : € 32.881.05	Consultant and lecture activities (biomarker testing; e. g. HER2 low/ultralow, BRCA1/2, PIK3CA)
		9/2021 – present	- QuIP (Qualitätssicherungs-Initiative Pathologie) GmbH, Germany honorary : € 42.947	Consultant (information platform on biomarker testing, proficiency testing); writing activities, lecture activities
		10/2021	- Myriad Genetics SAS, France honorary : € 1.000	Lecture Activities (multigene tests)
		7/2021 – 4/2022	- Diaceutics, UK honorary : € 1.650	Steering Committee (investigation on HER2 low testing)
		9/2021 – 2/2023	- If Kongress Management, Germany honorary and travel fees: € 848	Lecture Activities (biomarker testing, e. g. HER2 low testing)

		4/2023	- Streamedup! honorary: € 1.500	Lecture activities (HER2 low testing)
		7/2023	- Veracyte Inc. honorary: € 1.200	Lecture activities (symposium chair; breast cancer subtyping)
		9/2023	- Delphi Int. honorary: € 1.325	Lecture activities (HER2 low testing)
		4/2024	- Barmer IfG Gesundheitswesen honorary; € 500	Writing activities (biomarker testing breast cancer)
		6/2024	- Menarini Stemline honorary: € 1.100	Lecture activities (PD-L1 testing)
		8/2024	- Gilead travel fees and honorary: € 2.295,52	Consultant (biomarker testing ADCs)
		11/2024	- Eurobio Scientific Service GmbH honorary: €2.100	Consultant (gene expression testing)
		3/2025	- EUREF honorary: € 1.150	Consultant (recertification audit)
				I have been asked for single invited presentations on various subjects of breast and surgical pathology on the occasion of scientific meetings. Additionally, I have been asked to perform scientific advisory services by attending single National or European Pathology or Oncology Advisory Board Meetings. The key aspects are

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
				the identification of predictive markers for breast cancer treatment, especially targeted therapies.
<b>C. Non-remunerated post</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'ye's, please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> </ul>	[Please describe your role.]
<b>D. Legal representation<sup>5</sup></b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If 'yes', please specify: <ul style="list-style-type: none"> <li>• Name of the entity;</li> <li>• Place;</li> <li>• Type of the entity: public, private;</li> </ul>	[Please describe your role.]

<sup>5</sup> **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<p><b>3. Regarding research related to breast cancer within the past 5 years:</b></p> <p><b>A. Have you been an investigator in research studies on breast cancer?</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	If ‘yes’, please specify if you have been a principal investigator. Please mention the title of each study.	[Please describe the study, your role in the study and mention if the results of the study have been published.]
<p><b>B. If yes, for the aforementioned research studies, did you receive support<sup>6</sup>?</b></p>	Yes <input type="checkbox"/> No <input type="checkbox"/>	MM/YYYY – MM/YYYY	If ‘yes’, please specify: <ul style="list-style-type: none"> <li>• Type of received support: grants, funds;</li> <li>• Entity which offered the support: name, place, type (public, private);</li> <li>• Received amounts (for public grants please also specify the annual budget of your home institution).</li> </ul>	[Please mention the title of the studies you refer to.]

<sup>6</sup> **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

Activities (September 2021 - September 2025)	Yes/No	Period (From - To)	Information	Details
<b>4. Do you have membership in national or international organisations<sup>7</sup>, including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision-making bodies with an interest in breast cancer?</b>	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	2001 – Present	German Cancer Society (Deutsche Krebsgesellschaft e. V.), German Society of Senology (Deutsche Gesellschaft für Senologie e. V.), Berlin	Member of Steering Committee Function as expert: Chair of the Breast Pathology Working Group Function of body: Development of National Guidelines for the Early Detection, Diagnosis and Therapy of Breast Cancer Link to website of body: <a href="https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom">https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom</a>
		12/2009 – Present	Cooperation alliance mammography (Kooperationsgemeinschaft Mammographie GBR), Berlin	Member of Scientific advisory council Function of expert: Representative for Pathology Function of body: Scientific advice for the Kooperationsgemeinschaft Mammographie Link to website of body: <a href="http://www.mammo-programm.de/">http://www.mammo-programm.de/</a>

<sup>7</sup> **Organisation** refers to a governmental, international or non-profit organisation.

		2012 - Present	German Cancer Society (Deutsche Krebsgesellschaft e. V.), Berlin	Member of the Certification Commissions “breast cancer centres” and “ Function of expert: Representative of the German Society of Pathology and the Federal Association of German Pathologists Function of body: Compilation of the catalogue of requirements Link to website of body: <a href="https://www.krebsgesellschaft.de/unsere-themen/zertifizierung/kommissionen-und-protokolle">https://www.krebsgesellschaft.de/unsere-themen/zertifizierung/kommissionen-und-protokolle</a>
		2016 - Present	Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG), Berlin	Member of the Federal Group « Breast surgery » Function of expert: Pathology expert Function of body: Advice on the interpretation of the results of quality assurance and on the further development, revision and maintenance of quality assurance procedures <a href="https://iqtig.org/qs-verfahren/mamma/">https://iqtig.org/qs-verfahren/mamma/</a>
		2017 – 2023	German Society of Pathology (Deutsche Gesellschaft für Pathologie), Berlin	Board Member
		2019 - Present	German Society of Senology (Deutsche Gesellschaft für Senologie e. V.), Berlin	Board Member, Representative for Pathology

		2019 - Present	German Cancer Society (Deutsche Krebsgesellschaft e. V.), Berlin	Member of the Certification Commission “Centres for Familial Breast and Ovarian Cancer” Function of expert: Representative of the German Society of Pathology Function of body: Compilation of the catalogue of requirements Link to website of body: <a href="https://www.krebsgesellschaft.de/unsere-themen/zertifizierung/kommissionen-und-protokolle">https://www.krebsgesellschaft.de/unsere-themen/zertifizierung/kommissionen-und-protokolle</a>
		2019 - Present	Federal Association of German Pathologists (Bundesverband Deutscher Pathologen)	Vice President
		2023- Present	International Academy of Pathology (IAP), German Division	Member of the Nomination Committee
<b>5. Do you have intellectual property rights (IPR)<sup>8</sup> related to breast cancer?</b>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]

<sup>8</sup> **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

<p><b>6. Within the past 5 years:</b></p> <p><b>A. Have you provided any expert opinion or testimony in the field of breast cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
<p><b>B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of breast cancer?</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
<p><b>7. Do any of your immediate family members<sup>9</sup> have direct interests related to breast cancer that could undermine your independence?</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]
<p><b>8. Within the past 5 years, did you take part in other activities with interests related to breast cancer?</b></p>	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	MM/YYYY – MM/YYYY	Please specify the title of the activity.	[Please describe the activity.]

**Notes:**

---

<sup>9</sup> **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published<sup>10</sup> before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: [JRC-CANCER-POLICY-SUPPORT@ec.europa.eu](mailto:JRC-CANCER-POLICY-SUPPORT@ec.europa.eu).

- I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the ECIBC membership<sup>11</sup>.
- I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725<sup>12</sup>.

**Name and Surname:** Prof. Dr. Annette Lebeau

**Date:** 15.9.2025

**Signature:**



**Place:** Herrnburg

---

<sup>10</sup> Personal data processing including the DoI

<https://ec.europa.eu/dpo-register/detail/DPR-EC-00656>

<sup>11</sup> Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

<sup>12</sup> Protection of individuals with regard to the processing of personal data

<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>